胰激肽原酶联合贝那普利对糖尿病肾病患者疗效、尿微量白蛋白/尿肌酐比值及25(OH)D_(3)水平的影响  

Effects of pancreatic kininogenase combined with benazepril on curative effect, UACR and 25(OH)D_(3) level of diabetic nephropathy

作　　者：汝燕[1] 魏苏 李庆凤 赵静[1] RU Yan;WEI Su;LI Qing-feng(Department of Endocrinology,Suzhou Hospital of Anhui Medical University(Suzhou Municipal Hospital of Anhui Province)Suzhou Anhui 234000,China)

机构地区：[1]安徽医科大学附属宿州医院(安徽省宿州市立医院)内分泌科,安徽宿州234000

出　　处：《临床和实验医学杂志》2021年第11期1170-1174,共5页Journal of Clinical and Experimental Medicine

基　　金：安徽省重点研究与开发计划(编号:S202004j07020052)。

摘　　要：目的探究胰激肽原酶联合贝那普利对糖尿病肾病(DN)患者疗效、尿微量白蛋白/尿肌酐比值(UACR)及25-羟维生素D_(3)[25(OH)D_(3)]水平的影响。方法前瞻性选取2018年3月至2019年12月安徽医科大学附属宿州医院收治的DN患者125例作为研究对象。采用Excel表格将患者编号后随机分为胰激肽原酶组63例与对照组62例,对照组采用贝那普利治疗,胰激肽原酶组采用胰激肽原酶联合贝那普利治疗。对比2组患者的临床疗效,观察治疗前、治疗3个月后血糖[空腹血糖(FBG)、糖化血红蛋白(HbA1C)]、血压[收缩压、舒张压]、空腹胰岛素(FINS)水平,肾功能指标[24 h尿微量白蛋白排泄率(UAER)、24 h尿蛋白定量及UACR]及25(OH)D_(3)水平。结果胰激肽原酶组总有效率90.48%,高于对照组的77.42%,差异有统计学意义(P<0.05)。治疗前,2组患者血糖、血压、FINS、肾功能指标、25(OH)D_(3)水平比较,差异均无统计学意义(P>0.05);治疗3个月后,胰激肽原酶组患者FBG、HbA1C、24 h UAER、24 h尿蛋白定量、UACR水平均低于对照组,差异均有统计学意义(P<0.05);治疗3个月后,2组患者血压、FINS水平比较,差异无统计学意义(P>0.05);治疗3个月后,胰激肽原酶组25(OH)D_(3)水平高于对照组,差异有统计学意义(P<0.05)。结论胰激肽原酶联合贝那普利可提高DN疗效,降低蛋白尿水平,改善维生素缺乏,具有良好的肾脏保护作用。Objective To explore the effects of pancreatic kininogenase combined with benazepril on curative effect,urinary microalbuminuria/creatinine ratio(UACR)and 25 hydroxyvitamin D_(3)[25(OH)D_(3)]level of diabetic nephropathy(DN).Methods A total of 125 patients with DN in our hospital were selected,and the sample selection period was from March 2018 to December 2019.The patients were numbered by Excel and randomly divided into pancreatic kininogenase group 63 cases and control group 62 cases.The control group was treated with benazepril,and the pancreatic kininogenase group was treated with pancreatic kininogenase combined with benazepril.Clinical efficacy of the two groups of patients,observe the blood glucose[fasting blood glucose(FBG),hemoglobin A1C(HbA1C)],blood pressure[systolic blood pressure,diastolic blood pressure],fasting insulin(FINS)levels before treatment and 3 months after treatment[24-hour urine microalbumin excretion rate(UAER),24-hour urine protein quantification and UACR]and 25(OH)D_(3) levels were compared.Results The total effective rate of pancreatic kininogenase group was 90.48%,which was higher than 77.42%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in blood glucose,blood pressure,FINS,renal function indexes,and 25(OH)D_(3) levels between the two groups of patients(P>0.05);after 3 months of treatment,FBG in the pancreatic kininogenase group,HbA1C,24 h UAER,24 h urine protein quantification,and UACR levels were lower than those of the control group,the differences were statistically significant(P<0.05);after 3 months of treatment,there was no significant difference in blood pressure and FINS levels between the two groups Significance(P>0.05);after 3 months of treatment,the level of 25(OH)D_(3) in the pancreatic kininogenase group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Pancreatic kininogenase combined with benazepril can improve the curative e

关 键 词：糖尿病肾病 胰激肽原酶 贝那普利 尿微量白蛋白 尿肌酐 25-羟维生素D_(3) 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]